Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| AI438-020 | Other Identifier | Bristol-Myers Squibb |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| GlaxoSmithKline | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine if there is an interaction in healthy subjects taking BMS-663068 with Darunavir/Ritonavir and/or Etravirine.
Brief title: drug-drug interaction (DDI)
Primary Purpose: Other : Phase 1 Clinical Pharmacology drug interaction study in healthy subjects
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cohort 1: BMS-663068+DRV/RTV | Experimental | Extended release tablet BMS-663068 600mg orally twice daily on days 1-4 and 17-26. Tablet DRV 600mg / RTV 100mg orally orally twice daily on days 7-16 |
|
| Cohort 2: BMS-663068+ETR | Experimental | Extended release tablet BMS-663068 600mg orally twice daily on days 1-4 and 17-26. Tablet ETR 200mg orally orally twice daily on days 7-16 |
|
| Cohort 3: BMS-663068+DRV/RTV+ETR | Experimental | Extended release tablet BMS-663068 600mg orally twice daily on days 1-4 and 17-26. Tablet DRV 600mg / RTV 100mg and ETR 200mg orally orally twice daily on days 7-16 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| BMS-663068 | Drug | BMS-663068 |
|
| Measure | Description | Time Frame |
|---|---|---|
| Maximum observed plasma concentration (Cmax) of BMS-626529 | 20 timepoints up to day 26 | |
| Area under the concentration-time curve in 1 dosing interval (AUC(TAU)) of BMS-626529 | 20 timepoints up to day 26 |
| Measure | Description | Time Frame |
|---|---|---|
| Time of maximum observed plasma concentration (Tmax) for BMS-626529, DRV, RTV, and ETR | Up to day 26 (20 timepoints for BMS-626529, 24 timepoints for DRV, RTV and ETR) | |
| Concentration at 12 hours (C12) for BMS-626529, DRV, RTV, and ETR | Up to day 26 (20 timepoints for BMS-626529, 24 timepoints for DRV, RTV and ETR) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| GSK Clinical Trials | ViiV Healthcare | Study Director |
Not provided
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 35315687 | Derived | Moore K, Thakkar N, Magee M, Sevinsky H, Vakkalagadda B, Lubin S, Llamoso C, Ackerman P. Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants. Antimicrob Agents Chemother. 2022 Apr 19;66(4):e0225121. doi: 10.1128/aac.02251-21. Epub 2022 Mar 22. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D007239 | Infections |
| D000163 | Acquired Immunodeficiency Syndrome |
| ID | Term |
|---|---|
| D015658 | HIV Infections |
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D015229 | Sexually Transmitted Diseases, Viral |
Not provided
Not provided
| ID | Term |
|---|---|
| C576364 | fostemsavir |
| D000069454 | Darunavir |
| D019438 | Ritonavir |
| C451734 | etravirine |
| ID | Term |
|---|---|
| D013449 | Sulfonamides |
| D000577 | Amides |
| D009930 | Organic Chemicals |
| D002219 | Carbamates |
| D000144 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Darunavir (DRV) | Drug | Darunavir (DRV) |
|
|
| Ritonavir (RTV) | Drug | Ritonavir (RTV) |
|
|
| Etravirine (ETR) | Drug | Etravirine (ETR) |
|
|
| Trough observed plasma concentration (Ctrough) for BMS-626529, DRV, RTV, and ETR | Up to day 26 (20 timepoints for BMS-626529, 24 timepoints for DRV, RTV and ETR) |
| Cmax for DRV, RTV, and ETR | 24 timepoints up to 26 day |
| AUC(TAU) for DRV, RTV, and ETR | 24 timepoints up to 26 day |
| Safety and tolerability endpoints include incidence of adverse event (AEs), serious adverse event (SAEs), AEs leading to discontinuation, deaths, marked laboratory abnormalities, and abnormalities in vital signs, physical examination, and 12-lead ECGs | Up to day 27 |
| D012749 | Sexually Transmitted Diseases |
| D016180 | Lentivirus Infections |
| D012192 | Retroviridae Infections |
| D012327 | RNA Virus Infections |
| D014777 | Virus Diseases |
| D012897 | Slow Virus Diseases |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D007153 | Immunologic Deficiency Syndromes |
| D007154 | Immune System Diseases |
| Acids, Acyclic |
| D002264 | Carboxylic Acids |
| D013450 | Sulfones |
| D013457 | Sulfur Compounds |
| D005663 | Furans |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D013844 | Thiazoles |
| D001393 | Azoles |